Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 18/20 | 0.58 |
| ▸ | HSD11B2 | P80365 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1844175 | 1.00 | HSD11B1 (0.58) | HSD11B1HSD11B2MEN1MAPK1KMT2A | |
| SCHEMBL1844176 | 1.00 | HSD11B1 (0.58) | HSD11B1HSD11B2MEN1MAPK1KMT2A | |
| SCHEMBL1845148 | 0.88 | HSD11B1 (0.47) | HSD11B1HSD11B2MEN1MAPK1KMT2A | |
| SCHEMBL1845149 | 0.88 | HSD11B1 (0.47) | HSD11B1HSD11B2MEN1MAPK1KMT2A | |
| SCHEMBL31647199 | 0.88 | HSD11B1 (0.47) | HSD11B1HSD11B2MEN1MAPK1KMT2A | |
| SCHEMBL1845150 | 0.88 | HSD11B1 (0.47) | HSD11B1HSD11B2MEN1MAPK1KMT2A | |
| SCHEMBL12579046 | 0.82 | HSD11B1 (0.45) | HSD11B1HSD11B2MEN1MAPK1KMT2A | |
| SCHEMBL1847714 | 0.81 | HSD11B1 (0.42) | HSD11B1HSD11B2MEN1MAPK1KMT2A | |
| SCHEMBL1847717 | 0.81 | HSD11B1 (0.42) | HSD11B1HSD11B2MEN1MAPK1KMT2A | |
| SCHEMBL1847712 | 0.81 | HSD11B1 (0.42) | HSD11B1HSD11B2MEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-30 | — | — | US | disclosed |
| EP-2325175-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2011-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | PRKCZ, DCLK1, AAK1 | HSD11B1 2713/4885HSD11B2 2516/4885MEN1 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.